Protective Effect of Pemafibrate Treatment against Diabetic Retinopathy in Spontaneously Diabetic Torii Fatty Rats

Diabetic retinopathy (DR) can cause visual impairment and blindness, and the increasing global prevalence of diabetes underscores the need for effective therapies to prevent and treat DR. Therefore, this study aimed to evaluate the protective effect of pemafibrate treatment against DR, using a Spont...

Full description

Saved in:
Bibliographic Details
Published inBiological & pharmaceutical bulletin Vol. 47; no. 3; pp. 713 - 722
Main Authors Tanaka, Yoshiaki, Takagi, Rina, Mitou, Shingen, Shimmura, Machiko, Hasegawa, Tetsuya, Amarume, Jota, Shinohara, Masami, Kageyama, Yasushi, Sasase, Tomohiko, Ohta, Takeshi, Muramatsu, Shin-ichi, Kakehashi, Akihiro, Kaburaki, Toshikatsu
Format Journal Article
LanguageEnglish
Published Japan The Pharmaceutical Society of Japan 27.03.2024
Japan Science and Technology Agency
Subjects
Animals
Aquaporin 4
Benzoxazoles
Blood levels
Body weight
Butyrates
Cholesterol
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Diabetic retinopathy
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - prevention & control
Disease Models, Animal
Electroretinograms
Food consumption
High density lipoprotein
pemafibrate
Rats
Rats, Sprague-Dawley
Retina
Retinopathy
Spontaneously Diabetic Torii fatty rat model
Spontaneously Diabetic Torii fatty rat model
pemafibrate
aquaporin-4
diabetic retinopathy
Online AccessGet full text

Cover

Abstract Diabetic retinopathy (DR) can cause visual impairment and blindness, and the increasing global prevalence of diabetes underscores the need for effective therapies to prevent and treat DR. Therefore, this study aimed to evaluate the protective effect of pemafibrate treatment against DR, using a Spontaneously Diabetic Torii (SDT) fatty rat model of obese type 2 diabetes. SDT fatty rats were fed either a diet supplemented with pemafibrate (0.3 mg/kg/d) for 16 weeks, starting at 8 weeks of age (Pf SDT fatty: study group), or normal chow (SDT fatty: controls). Normal chow was provided to Sprague–Dawley (SD) rats (SD: normal controls). Electroretinography (ERG) was performed at 8 and 24 weeks of age to evaluate the retinal neural function. After sacrifice, retinal thickness, number of retinal folds, and choroidal thickness were evaluated, and immunostaining was performed for aquaporin-4 (AQP4). No significant differences were noted in food consumption, body weight, or blood glucose level after pemafibrate administration. Triglyceride levels were reduced, and high-density lipoprotein cholesterol levels were increased. Extension of oscillatory potential (OP)1 and OP3 waves on ERG was suppressed in the Pf SDT fatty group. Retinal thickness at 1500 microns from the optic disc improved in the Pf SDT fatty group. No significant improvements were noted in choroidal thickness or number of retinal folds. Quantitative analyses showed that AQP4-positive regions in the retinas were significantly larger in the Pf SDT fatty group than in the SDT fatty group. The findings suggest that pemafibrate treatment can exert protective effects against DR.
AbstractList Diabetic retinopathy (DR) can cause visual impairment and blindness, and the increasing global prevalence of diabetes underscores the need for effective therapies to prevent and treat DR. Therefore, this study aimed to evaluate the protective effect of pemafibrate treatment against DR, using a Spontaneously Diabetic Torii (SDT) fatty rat model of obese type 2 diabetes. SDT fatty rats were fed either a diet supplemented with pemafibrate (0.3 mg/kg/d) for 16 weeks, starting at 8 weeks of age (Pf SDT fatty: study group), or normal chow (SDT fatty: controls). Normal chow was provided to Sprague–Dawley (SD) rats (SD: normal controls). Electroretinography (ERG) was performed at 8 and 24 weeks of age to evaluate the retinal neural function. After sacrifice, retinal thickness, number of retinal folds, and choroidal thickness were evaluated, and immunostaining was performed for aquaporin-4 (AQP4). No significant differences were noted in food consumption, body weight, or blood glucose level after pemafibrate administration. Triglyceride levels were reduced, and high-density lipoprotein cholesterol levels were increased. Extension of oscillatory potential (OP)1 and OP3 waves on ERG was suppressed in the Pf SDT fatty group. Retinal thickness at 1500 microns from the optic disc improved in the Pf SDT fatty group. No significant improvements were noted in choroidal thickness or number of retinal folds. Quantitative analyses showed that AQP4-positive regions in the retinas were significantly larger in the Pf SDT fatty group than in the SDT fatty group. The findings suggest that pemafibrate treatment can exert protective effects against DR.
ArticleNumber b23-00872
Author Tanaka, Yoshiaki
Kageyama, Yasushi
Hasegawa, Tetsuya
Mitou, Shingen
Shimmura, Machiko
Sasase, Tomohiko
Amarume, Jota
Ohta, Takeshi
Muramatsu, Shin-ichi
Kakehashi, Akihiro
Takagi, Rina
Shinohara, Masami
Kaburaki, Toshikatsu
Author_xml – sequence: 1
  fullname: Tanaka, Yoshiaki
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
– sequence: 2
  fullname: Takagi, Rina
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
– sequence: 3
  fullname: Mitou, Shingen
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
– sequence: 4
  fullname: Shimmura, Machiko
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
– sequence: 5
  fullname: Hasegawa, Tetsuya
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
– sequence: 6
  fullname: Amarume, Jota
  organization: Medical Affairs Department, Kowa Company, Ltd
– sequence: 7
  fullname: Shinohara, Masami
  organization: Tokyo Animal & Diet Department, CLEA Japan, Inc
– sequence: 8
  fullname: Kageyama, Yasushi
  organization: Tokyo Animal & Diet Department, CLEA Japan, Inc
– sequence: 9
  fullname: Sasase, Tomohiko
  organization: Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc
– sequence: 10
  fullname: Ohta, Takeshi
  organization: Laboratory of Animal Physiology and Functional Anatomy, Graduate School of Agriculture, Kyoto University
– sequence: 11
  fullname: Muramatsu, Shin-ichi
  organization: Division of Neurological Gene Therapy, Center for Open Innovation, Jichi Medical University
– sequence: 12
  fullname: Kakehashi, Akihiro
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
– sequence: 13
  fullname: Kaburaki, Toshikatsu
  organization: Department of Ophthalmology, Jichi Medical University, Saitama Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38432946$$D View this record in MEDLINE/PubMed
BookMark eNpdkc1r3DAQxUVJaTZJj70WQS-9ONWXLftYtvkoBBKS7VmMteNEiy25kraw_32VbLqFXN4MzI_HY94JOfLBIyGfODvnQrXf-rk_74WsGGu1eEcWXCpd1YLXR2TBOt5WDa_bY3KS0oYxppmQH8ixbJUUnWoWJN7FkNFm9wfpxTCUjYaB3uEEg-sjZKSriJAn9JnCIzifMv3hoMfsLL0v6sMM-WlHnacPc_AZPIZtGnf_qVWIztFLyHlH7yGnM_J-gDHhx9d5Sn5dXqyW19XN7dXP5febyqquy5US3IJuhnrdaMY1aJQ178HWoHtrgbf1ulOSDVIzCwzqNQMlOyFAdFBrzeUp-br3nWP4vcWUzeSSxXHcRzSik1rKRjJZ0C9v0E3YRl_SmXJuRcMlV4Wq9pSNIaWIg5mjmyDuDGfmuQxTyjClDPNSRuE_v7pu-wnXB_rf9wuw3AOblOERDwDE8rcRX-yUNvJZDraHq32CaNDLv6syn2M
Cites_doi 10.4103/jrms.JRMS_772_19
10.1155/EDR.2000.89
10.1001/archopht.1962.00960030023005
10.2337/dc15-2171
10.1007/s00125-010-1971-x
10.1538/expanim.14-0084
10.3390/ijms20225682
10.1007/s00441-014-2089-0
10.1016/j.jacl.2017.10.006
10.1097/IAE.0000000000001158
10.1177/147323001103900214
10.2337/dc11-1909
10.1016/j.lfs.2016.01.042
10.1155/2019/8724818
10.1186/s12933-017-0602-y
10.1177/2042018813477886
10.1007/s11883-020-0823-5
10.1016/j.ophtha.2021.04.027
10.1007/s00417-017-3631-z
10.1248/bpb.b23-00336
10.1172/JCI27989
10.33549/physiolres.933709
10.1016/j.exer.2012.02.013
10.1073/pnas.1307211110
10.1167/iovs.13-13127
10.1186/s40662-021-00237-3
10.1016/S0149-2918(02)80095-9
10.1538/expanim.57.111
10.1038/21224
10.1016/j.amjcard.2006.11.016
10.1016/S0140-6736(07)61607-9
10.3390/ijms21176243
10.2147/DMSO.S4170
10.1139/Y08-043
10.1002/0471142735.im1506s53
10.1016/j.diabres.2017.03.024
10.1186/1475-2840-12-82
10.3390/ijms20235878
10.1016/S1350-9462(97)00005-0
10.1016/j.ophtha.2014.07.019
10.1538/expanim.60.481
10.1016/j.ajpath.2014.06.021
10.5551/jat.28720
10.1167/iovs.18-25372
10.3390/pharmaceutics14020384
ContentType Journal Article
Copyright 2024 The Pharmaceutical Society of Japan
Copyright Japan Science and Technology Agency 2024
Copyright_xml – notice: 2024 The Pharmaceutical Society of Japan
– notice: Copyright Japan Science and Technology Agency 2024
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
DOI 10.1248/bpb.b23-00872
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-5215
EndPage 722
ExternalDocumentID 10_1248_bpb_b23_00872
38432946
article_bpb_47_3_47_b23_00872_article_char_en
Genre Journal Article
GroupedDBID ---
23N
2WC
5GY
6J9
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
HH5
JMI
JSF
JSH
KQ8
MOJWN
OK1
P2P
RJT
RZJ
TR2
XSB
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c499t-421ca76f5d67017a7e351bac5a7bcca185d9430f370ca0a5d0a43922a29a57713
ISSN 0918-6158
IngestDate Sat Jun 22 20:57:46 EDT 2024
Fri Sep 13 05:59:43 EDT 2024
Fri Aug 23 01:03:20 EDT 2024
Sat Mar 30 01:44:32 EDT 2024
Fri Apr 12 19:05:34 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Spontaneously Diabetic Torii fatty rat model
pemafibrate
aquaporin-4
diabetic retinopathy
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c499t-421ca76f5d67017a7e351bac5a7bcca185d9430f370ca0a5d0a43922a29a57713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/bpb/47/3/47_b23-00872/_article/-char/en
PMID 38432946
PQID 3038261314
PQPubID 1966364
PageCount 10
ParticipantIDs proquest_miscellaneous_2937336303
proquest_journals_3038261314
crossref_primary_10_1248_bpb_b23_00872
pubmed_primary_38432946
jstage_primary_article_bpb_47_3_47_b23_00872_article_char_en
PublicationCentury 2000
PublicationDate 2024-Mar-27
PublicationDateYYYYMMDD 2024-03-27
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-Mar-27
  day: 27
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Biological & pharmaceutical bulletin
PublicationTitleAlternate Biol Pharm Bull
PublicationYear 2024
Publisher The Pharmaceutical Society of Japan
Japan Science and Technology Agency
Publisher_xml – name: The Pharmaceutical Society of Japan
– name: Japan Science and Technology Agency
References 26) Motohashi Y, Kemmochi Y, Maekawa T, Tadaki H, Sasase T, Tanaka Y, Kakehashi A, Yamada T, Ohta T. Diabetic macular edema-like ocular lesions in male spontaneously diabetic torii fatty rats. Physiol. Res., 67, 423–432 (2018).
6) Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin. Ther., 24, 2022–2050 (2002).
38) Kida T, Oku H, Horie T, Fukumoto M, Okuda Y, Morishita S, Ikeda T. Implication of VEGF and aquaporin 4 mediating Müller cell swelling to diabetic retinal edema. Graefes Arch. Clin. Exp. Ophthalmol., 255, 1149–1157 (2017).
18) Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. J. Clin. Invest., 116, 571–580 (2006).
45) Takakura S, Toyoshi T, Hayashizaki Y, Takasu T. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in Spontaneously Diabetic Torii fatty rats. Life Sci., 147, 125–131 (2016).
8) Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology, 121, 2443–2451 (2014).
17) Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J. Clin. Lipidol., 12, 173–184 (2018).
42) Taylor CR. Quantitative in situ proteomics; a proposed pathway for quantification of immunohistochemistry at the light-microscopic level. Cell Tissue Res., 360, 109–120 (2015).
33) Spaide RF. Retinal vascular cystoid macular edema: review and new theory. Retina, 36, 1823–1842 (2016).
37) Zhang Y, Xu G, Ling Q, Da C. Expression of aquaporin 4 and Kir4.1 in diabetic rat retina: treatment with minocycline. J. Int. Med. Res., 39, 464–479 (2011).
39) Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells. Invest. Ophthalmol. Vis. Sci., 43, 3109–3116 (2002). https://iovs.arvojournals.org/article.aspx?articleid=2162845
20) Wang F, Gao L, Gong B, Hu J, Li M, Guan Q, Zhao J. Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Can. J. Physiol. Pharmacol., 86, 465–471 (2008).
28) Kawai S, Takagi Y, Kaneko S, Kurosawa T. Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp. Anim., 60, 481–487 (2011).
46) Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse. Curr. Protoc. Immunol., 53, 15.6.1–15.6.20 (2003).
43) Shinohara M, Masuyama T, Shoda T, Takahashi T, Katsuda Y, Komeda K, Kuroki M, Kakehashi A, Kanazawa Y. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int. J. Exp. Diabetes Res., 1, 89–100 (2000).
29) Yonemura D, Aoki T, Tsuzuki K. Electroretinogram in diabetic retinopathy. Arch. Ophthalmol., 68, 19–24 (1962).
31) Sergeys J, Etienne I, Van Hove I, Lefevere E, Stalmans I, Feyen JHM, Moons L, Van Bergen T. Longitudinal in vivo characterization of the streptozotocin-induced diabetic mouse model: focus on early inner retinal responses. Invest. Ophthalmol. Vis. Sci., 60, 807–822 (2019).
44) Katsuda Y, Sasase T, Tadaki H, Mera Y, Motohashi Y, Kemmochi Y, Toyoda K, Kakimoto K, Kume S, Ohta T. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin. Exp. Anim., 64, 161–169 (2015).
23) Moran E, Ding L, Wang Z, Cheng R, Chen Q, Moore R, Takahashi Y, Ma JX. Protective and antioxidant effects of PPARα in the ischemic retina. Invest. Ophthalmol. Vis. Sci., 55, 4568–4576 (2014).
22) Ding L, Cheng R, Hu Y, Takahashi Y, Jenkins AJ, Keech AC, Humphries KM, Gu X, Elliott MH, Xia X, Ma JX. Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina. Am. J. Pathol., 184, 2709–2720 (2014).
19) Desouza CV, Rentschler L, Fonseca V. Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. Diabetes Metab. Syndr. Obes., 2, 165–172 (2009).
14) Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc. Diabetol., 16, 124 (2017).
24) Tomita Y, Ozawa N, Miwa Y, Ishida A, Ohta M, Tsubota K, Kurihara T. Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model. Int. J. Mol. Sci., 20, 5878 (2019).
40) Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399, 601–605 (1999).
3) Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract., 128, 40–50 (2017).
5) Hammes HP. Optimal treatment of diabetic retinopathy. Ther. Adv. Endocrinol. Metab., 4, 61–71 (2013).
25) Matsui K, Ohta T, Oda T, Sasase T, Ueda N, Miyajima K, Masuyama T, Shinohara M, Matsushita M. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats. Exp. Anim., 57, 111–121 (2008).
4) Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care, 39, 1643–1649 (2016).
9) Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol., 99 (6A), 3C–18C (2007).
10) Emami F, Hariri A, Matinfar M, Nematbakhsh M. Fenofibrate-induced renal dysfunction, yes or no? J. Res. Med. Sci., 25, 39 (2020).
13) Raza-Iqbal S, Tanaka T, Anai M, Inagaki T, Matsumura Y, Ikeda K, Taguchi A, Gonzalez FJ, Sakai J, Kodama T. Transcriptome analysis of K-877 (a novel selective PPARα modulator (SPPARMα))-regulated genes in primary human hepatocytes and the mouse liver. J. Atheroscler. Thromb., 22, 754–772 (2015).
7) Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d’Emden MC, Crimet DC, O’Connell RL, Colman PG. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, 370, 1687–1697 (2007).
34) Curtis TM, Hamilton R, Yong PH, McVicar CM, Berner A, Pringle R, Uchida K, Nagai R, Brockbank S, Stitt AW. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia, 54, 690–698 (2011).
36) Wang T, Zhang C, Xie H, Jiang M, Tian H, Lu L, Xu GT, Liu L, Zhang J. Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy. Eye Vis. (Lond.), 8, 13 (2021).
35) Cui B, Sun JH, Xiang FF, Liu L, Li WJ. Aquaporin 4 knockdown exacerbates streptozotocin-induced diabetic retinopathy through aggravating inflammatory response. Exp. Eye Res., 98, 37–43 (2012).
12) Fruchart JC. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc. Diabetol., 12, 82 (2013).
32) Tomita Y, Lee D, Miwa Y, Jiang X, Ohta M, Tsubota K, Kurihara T. Pemafibrate protects against retinal dysfunction in a murine model of diabetic retinopathy. Int. J. Mol. Sci., 21, 6243 (2020).
15) Sasaki Y, Raza-Iqbal S, Tanaka T, Murakami K, Anai M, Osawa T, Matsumura Y, Sakai J, Kodama T. Gene expression profiles induced by a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate. Int. J. Mol. Sci., 20, 5682 (2019).
16) Tomida J, Sato T, Yoshida T, Senda S, Nakatsuma A, Iihara N. Statin, ezetimibe, or fibrate initiation and subsequent use for the primary and secondary prevention of cardiovascular diseases among Japanese patients aged ≥55 years: a nationwide cohort study. Biol. Pharm. Bull., 46, 1548–1557 (2023).
27) Tanaka Y, Takagi R, Ohta T, Sasase T, Kobayashi M, Toyoda F, Shimmura M, Kinoshita N, Takano H, Kakehashi A. Pathological features of diabetic retinopathy in Spontaneously Diabetic Torii fatty rats. J. Diabetes Res., 2019, 8724818 (2019).
1) Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35, 556–564 (2012).
21) Hu Y, Chen Y, Ding L, He X, Takahashi Y, Gao Y, Shen W, Cheng R, Chen Q, Qi X, Boulton ME, Ma JX. Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc. Natl. Acad. Sci. U.S.A., 110, 15401–15406 (2013).
30) Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog. Retin. Eye Res., 17, 59–76 (1998).
41) Hanaguri J, Nagai N, Yokota H, Kushiyama A, Watanabe M, Yamagami S, Nagaoka T. Fenofibrate nano-eyedrops ameliorate retinal blood flow dysregulation and neurovascular coupling in type 2 diabetic mice. Pharmaceutics, 14, 384 (2022).
2) Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng CY. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology, 128, 1580–1591 (2021).
11) Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr. Atheroscler. Rep., 22, 5 (2020).
22
44
23
45
24
46
25
26
27
28
29
30
31
10
32
11
33
12
34
13
35
14
36
15
37
16
38
17
39
18
19
1
2
3
4
5
6
7
8
9
40
41
20
42
21
43
References_xml – ident: 10
  doi: 10.4103/jrms.JRMS_772_19
– ident: 39
– ident: 43
  doi: 10.1155/EDR.2000.89
– ident: 29
  doi: 10.1001/archopht.1962.00960030023005
– ident: 4
  doi: 10.2337/dc15-2171
– ident: 34
  doi: 10.1007/s00125-010-1971-x
– ident: 44
  doi: 10.1538/expanim.14-0084
– ident: 15
  doi: 10.3390/ijms20225682
– ident: 42
  doi: 10.1007/s00441-014-2089-0
– ident: 17
  doi: 10.1016/j.jacl.2017.10.006
– ident: 33
  doi: 10.1097/IAE.0000000000001158
– ident: 37
  doi: 10.1177/147323001103900214
– ident: 1
  doi: 10.2337/dc11-1909
– ident: 45
  doi: 10.1016/j.lfs.2016.01.042
– ident: 27
  doi: 10.1155/2019/8724818
– ident: 14
  doi: 10.1186/s12933-017-0602-y
– ident: 5
  doi: 10.1177/2042018813477886
– ident: 11
  doi: 10.1007/s11883-020-0823-5
– ident: 2
  doi: 10.1016/j.ophtha.2021.04.027
– ident: 38
  doi: 10.1007/s00417-017-3631-z
– ident: 16
  doi: 10.1248/bpb.b23-00336
– ident: 18
  doi: 10.1172/JCI27989
– ident: 26
  doi: 10.33549/physiolres.933709
– ident: 35
  doi: 10.1016/j.exer.2012.02.013
– ident: 21
  doi: 10.1073/pnas.1307211110
– ident: 23
  doi: 10.1167/iovs.13-13127
– ident: 36
  doi: 10.1186/s40662-021-00237-3
– ident: 6
  doi: 10.1016/S0149-2918(02)80095-9
– ident: 25
  doi: 10.1538/expanim.57.111
– ident: 40
  doi: 10.1038/21224
– ident: 9
  doi: 10.1016/j.amjcard.2006.11.016
– ident: 7
  doi: 10.1016/S0140-6736(07)61607-9
– ident: 32
  doi: 10.3390/ijms21176243
– ident: 19
  doi: 10.2147/DMSO.S4170
– ident: 20
  doi: 10.1139/Y08-043
– ident: 46
  doi: 10.1002/0471142735.im1506s53
– ident: 3
  doi: 10.1016/j.diabres.2017.03.024
– ident: 12
  doi: 10.1186/1475-2840-12-82
– ident: 24
  doi: 10.3390/ijms20235878
– ident: 30
  doi: 10.1016/S1350-9462(97)00005-0
– ident: 8
  doi: 10.1016/j.ophtha.2014.07.019
– ident: 28
  doi: 10.1538/expanim.60.481
– ident: 22
  doi: 10.1016/j.ajpath.2014.06.021
– ident: 13
  doi: 10.5551/jat.28720
– ident: 31
  doi: 10.1167/iovs.18-25372
– ident: 41
  doi: 10.3390/pharmaceutics14020384
SSID ssj0007023
Score 2.4489353
Snippet Diabetic retinopathy (DR) can cause visual impairment and blindness, and the increasing global prevalence of diabetes underscores the need for effective...
SourceID proquest
crossref
pubmed
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 713
SubjectTerms Animals
Aquaporin 4
Benzoxazoles
Blood levels
Body weight
Butyrates
Cholesterol
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Diabetic retinopathy
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - prevention & control
Disease Models, Animal
Electroretinograms
Food consumption
High density lipoprotein
pemafibrate
Rats
Rats, Sprague-Dawley
Retina
Retinopathy
Spontaneously Diabetic Torii fatty rat model
Title Protective Effect of Pemafibrate Treatment against Diabetic Retinopathy in Spontaneously Diabetic Torii Fatty Rats
URI https://www.jstage.jst.go.jp/article/bpb/47/3/47_b23-00872/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/38432946
https://www.proquest.com/docview/3038261314/abstract/
https://search.proquest.com/docview/2937336303
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biological and Pharmaceutical Bulletin, 2024/03/27, Vol.47(3), pp.713-722
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXKQLAXBB0fhYGMhPrSpbSxHacSL9PENCENTaKTxlNkJ04bSpOqTR_KH-Bvc20nTgpMAl6iKr75UM_JzbnOvdcIvU0mbCRkqjyuAuJR7qdeCLu8SSz5OOaxSEJdjXz5Kbi4ph9v2E2n86OVtbQt5TD-_se6kv9BFfYBrrpK9h-QdSeFHfAb8IUtIAzbv8L4yjZZ0Mk_VRdindGmliLVQXCpBtMmjXwmMlCCA5sBY7Lnyywv9ILEpvLv86rIQSeqYrv5tmuspsU6ywbnotRaXdiuT-4bcOYcp-bPar43Oy7bfb3N1EAuFkapfik28wyEazOyELPMVvnn7i1xCa5ma-Zm56b-y00FzbPlcmtWR9KrJs2zRdGeufCpTt2yjQCGynpbQjlEwraes3bHtgFnRTvS8q3cFq3-5vN9qusY5EoOpU883WPPb9sBZKulIQAJKfEn9JfO2_ZdXg3dQXd9PmHcePgmjuKgbKoGrXC1d3vXOkT366P3tM29ryDvZ-r2yMUomOkj9LAKPfCp5dFj1FF5Fx2d5qIsljvcxyYZ2Hxl6aIHZ_VCgF3Uv7LI7k7wtKnW25yYQ1zj890RWjd8xJaPuEhxi4_Y8RFXfMQ103CLjzjL8R4fGyvDR2z4iDUfn6Dr8w_TswuvWtPDiyG2Lj3qj2PBg5QlAYeXgeCKsLEUMRNcgjMB9ZjoBQFSwkexGAmWjARIZt8X_kQwDhR4ig7yIlfPEQ6SII7DUHIlUqrCVI5CoVJGKOOSwTl6qF-jEa1s65ZIh7yAYAQIRoBgZBDsofcWK2dWPdHGjPKI6I0zd6O6LhLcUA8d1whHlXPYRKAMIXAfkzHtoTduGIDT3-PsvxeB0tbNSMG0h55ZZrg7qCn14taRl-iweaiO0UG53qpXIJBL-dqQ9ycKisGt
link.rule.ids 315,786,790,27957,27958
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+Effect+of+Pemafibrate+Treatment+against+Diabetic+Retinopathy+in+Spontaneously+Diabetic+Torii+Fatty+Rats&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Tanaka%2C+Yoshiaki&rft.au=Takagi%2C+Rina&rft.au=Mitou%2C+Shingen&rft.au=Shimmura%2C+Machiko&rft.date=2024-03-27&rft.eissn=1347-5215&rft.volume=47&rft.issue=3&rft.spage=713&rft_id=info:doi/10.1248%2Fbpb.b23-00872&rft_id=info%3Apmid%2F38432946&rft.externalDocID=38432946
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon